Study Reveals How Pancreatic Cancer Cells Evolve to Evade Treatment

New York – October 13, 2026 – A comprehensive study has provided new insights into how pancreatic cancer cells continuously change their genetic structure to evade treatment and spread throughout the body. The analysis, led by researchers at NYU Langone Health and its Perlmutter Cancer Center, examined nearly half a million cancer cells from numerous patients.

Pancreatic cancer, particularly pancreatic ductal adenocarcinoma, is known for being difficult to treat, with a high mortality rate within five years of diagnosis. The research focused on mapping the genetic alterations within individual cancer cells, revealing how subpopulations of these cells reconfigure their DNA within the tumor over time.

The study identified a diverse array of cell clones within tumors, all sharing similar genetic backgrounds but exhibiting significantly different behaviors. Some clones evolved resistance to therapies, while others acquired the ability to spread aggressively. These findings suggest that the ongoing genetic reshaping of cancer cells is a key driver of both treatment resistance and metastasis.

Published in Nature Genetics, the research pinpointed specific genetic changes contributing to tumor evolution. For instance, increased activity of the MYC gene was linked to more aggressive cancer cell populations. Experiments showed that blocking MYC activity reverted these aggressive cells to a less aggressive form, potentially making them more vulnerable to immune attack.

The study also demonstrated how these cell clones influence the tumor's ability to evade immune detection. Increased activity in the TIGIT gene and suppressed activity in the PD1 gene within certain clones may explain the limited effectiveness of many immunotherapies against pancreatic cancer. Researchers believe that single-cell analysis offers a more effective approach to understanding complex cancers and targeting treatments.